DONATE TODAY
To Increase Patient Access

If you missed our May 2023 event, you can find it on our Facebook Page from the live stream or check back here where we'll be posting the fully edited Event Video along with the individual presentation videos.

TBA - May, 2024
11:00am - 1:30pm PST
Virtual Event via Zoom
2024 Event Sponsorship TBA
*If you are interested in submitting an application 
for sponsorship of this event, please CLICK HERE.
Previous Sponsors of "Know All Your Treatment Options":

"You can't know  about things you have yet to discover."

Yogi Berra
REGISTRATION OPENS IN APRIL 2024

MEET WITH OTHER PATIENTS, FAMILY MEMBERS, & CAREGIVERS

ASK QUESTIONS & FIND ANSWERS

2023 KEYNOTE SPEAKER

Dr. Thomas Lechner

Dr. Thomas Lechner joined Ono Pharma US in April 2022, assuming the role of Vice President, Medical Affairs, where he is responsible for establishing the company’s core medical strategy in the US.

Dr. Thomas Lechner from Ono Pharma US will be talking about a new research study that is underway for men and women with primary central nervous system lymphoma (PCNSL).
2023 PRESENTATION COMING SOON!
Prospect logo with bird
2023 SPEAKER

Ashley Bridwell

As the Rehab Program Coordinator at Barrow Neurological Institute
Ashley is the co-founder of the nation’s first program to address traumatic brain injury in the domestic violence population, She has dedicated her career as a social worker to address and bring awareness to traumatic brain injury in vulnerable populations through community and direct clinical care.
2023 PRESENTATION COMING SOON!
2023 SPEAKER

Dr. John Hood

Dr. Hood is a veteran of the California life science community who has founded and led several successful biotechnology companies in his 20-year career. He is currently Founder, CEO and Executive Chairman of Endeavor Biomedicines, a company funded in 2021 to develop novel therapeutics for oncology and idiopathic pulmonary fibrosis. Prior to that, John was the Founder and CEO of Impact Biomedicines (now owned by Bristol-Myers Squibb), the developer of fedratinib, which has subsequently been approved worldwide for the treatment of myelofibrosis. He began his career as Director of Research at TargeGen in 2001, where he co-discovered fedratinib and led a team identifying small molecule therapeutics for the treatment of cancer and eye disease. John is an inventor on 100+ patents and the author of 50+ scientific articles. He received his Ph.D. in Medical Physiology and a B.S. in Biochemistry from Texas A&M University.
2023 PRESENTATION COMING SOON!
2023 SPEAKER

Norman LaFrance, MD, ME, FACP, FACNP, FACNM

Chief Medical Officer, SVP of Plus Therapeutics
2023 PRESENTATION COMING SOON!
2023 SPEAKER

Leonardo Lustgarten, MD

Neurosurgeon, Radiosurgeon
Medical Director, Neurosurgery and Neuro-Oncology at Novcure
2023 PRESENTATION COMING SOON!
Hope Award 2023 poster

During this event, our 2023 HOPE Award winner will be announced!

If you haven't already nominated a Brain Tumor Patient who inspires you, be sure to do so by May 5th, 2023! Click the button below to nominate.
NOMINATION FORM
2023 SPEAKER

Dr. Jay McCracken, MD, FAANA

Dr. McCracken is a board-certified, fellowship trained Neurosurgical Oncologist who specializes in the surgical treatment of primary and metastatic tumors affecting the brain, pituitary gland and skull-base. He is well-versed in many different surgical approaches including open and minimally invasive craniotomies, endoscopic approaches to the skull base and pituitary gland, and stereotactic radiosurgery with both Gamma Knife and Linear Accelerator based technology. He leads the Piedmont Neurosurgical Oncology Service, is Co-Director of the Piedmont Brain Tumor Center.
2023 PRESENTATION COMING SOON!
2023 SPEAKER

Dr. David Andrews

Co-Founder & Chief Medical Officer, Imvax


2023 PRESENTATION COMING SOON!

Registration Opens in April 2024

2023 Event Agenda

DOWNLOAD PDF

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
Our Case For Change
EBCI In The News
Patient Support Services
Patient Resource Center
VOLUNTEER WITH EBCI
GET IN TOUCH
corporate partners
upcoming events
resources
About us
heartenvelopeusersphonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram